At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
Human Secretindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Secretin Infusion for Pain Due to Chronic Pancreatitis
In Brief
A Phase 2 clinical trial evaluating Human Secretin for Chronic Pancreatitis. Completed, enrolled 12 participants across 1 site.
Detailed Summary
* To determine if intravenous secretin administration in escalating doses three times daily for three days will improve the pain from CP at the time of infusion, after each infusion (1 to 3 hours), at Day 7 after infusion, and at Day 30 after infusion. * To validate the safety of intravenous secretin administration at the dosage indicated in this study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Pancreatitis
CountriesUnited States
CollaboratorsDartmouth-Hitchcock Medical Center
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2010
First PostedDec 2010
Primary CompletionDec 2011
Study CompletionApr 2012
TodayJul 2026
First PostedDec 23, 2010
Enrollment StartDec 1, 2010
Primary CompletionDec 1, 2011
Study CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 15.5 years ago
Interventions
Human Secretindrug
Dose Escalation